October 19, 2015
Allergen wraps up AqueSys buy (Including $300M up-front payment)
Allergan plc has completed the acquisition of AqueSys, Inc. a clinical-stage medical device company focused on developing ocular implants that…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
October 12, 2015
Quantum Pharma signs out-licensing deal for Aviticol in Germany
Quantum Pharma has signed an out-licensing agreement with a German pharmaceutical company for its first licensed product, a cholecalciferol 20 000IU capsule, marketed in the UK under the brand name Aviticol.
October 12, 2015
Physiomics sings new Virtual Tumour deal with new pharmaceutical company
Physiomics plc, the Oxford, UK based systems biology company has signed a new Virtual Tumour deal with a new pharmaceutical company, the 4th large pharma customer for this service.
October 12, 2015
Allergan’s AVYCAZTM potent in vitro activity against certain common Enterobacteriaceae pathogens
Allergan’s researchers have presented data at IDWeek from the International Network for Optimal Resistance Monitoring (INFORM) program that monitors the prevalence of resistant bacteria and changing trends of resistance, as well as the in vitro activity of antibiotics against these pathogens.
October 12, 2015
IONA test first trimester study
Premaitha Health plc, developer of the IONA test, the first CE-marked non-invasive prenatal screening test (NIPT), has announced the results of a study on the first-trimester detection of trisomy 21, 18 and 13 using the IONA test.
October 9, 2015
Roche buys Adheron
A research-based healthcare company, Roche, has bought Adheron Therapeutics
October 8, 2015
Verona Pharma welcomes new directors to the company
Verona Pharma plc, a London-listed drug development company focused on medicines to treat respiratory diseases, has appointed new Non-Executive Directors of the Company
October 7, 2015
Horizon In-licenses Oncology Programme from Servier and Enters Option Agreement
Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, has announced that its leveraged business unit has signed a programme in-licensing and option agreement with Servier, the independent French research-based pharmaceutical company .
October 7, 2015
Sanofi: New Analysis on Relapsing Multiple Sclerosis
Sanofi and its subsidiary Genzyme announced have that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate that Aubagio (teriflunomide) significantly slowed brain volume loss (or atrophy) vs. placebo over two years in people with relapsing multiple sclerosis (RMS).
October 7, 2015
AstraZeneca Completes Divestment of Rare Disease Medicine Caprelsa
AstraZeneca has announced the global completion of the divestment of Caprelsa (vandetanib), a rare disease medicine, to Genzyme, a Sanofi company.